C-Path Board Member Dr. Robert Califf Confirmed as New FDA Commissioner Statement from Critical Path Institute Board Chair Wainwright Fishburn on the Senate Confirmation of Dr. Robert M. Califf, MD, MAC
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit orga
January 31, 2022 The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions
January 19, 2022 Rare Diseases Cures Accelerator Data and Analytics Platform (RDCA-DAP) best practices and recommendations for FAIR data, toward alignment with International Regulatory agencies
C-Path Appoints Health Outcomes Expert as Executive Director of the Rare Disease COA Consortium Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA Consortium TUCSON, Ariz., January 13, 2022 — Critical Path Institut
C-Path Launches Rare Disease Clinical Outcome Assessment Consortium The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseas
C-Path’s ePRO Consortium Announces Rebranding, Changes Name to eCOA Consortium TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Report
January 11, 2022 DiMe Journal Club features Critical Path for Parkinson’s 3DT initiative Join 3DT and DiMe Society, January 11, to hear about 3DT recommendations for patient engagement. C-Path’s Critical Path for
Welcome uMotif C-Path is proud to welcome uMotif as the newest member of its Electronic Patient-Reported Outcome Consortium. Comprised of 15 fi
C-Path and NICHD to Share Real-world Data to Advance Neonatal Drug Development TUCSON, Ariz., Dec. 1, 2021 — Critical Path Institute’s (C-Path) International Neonatal Consortium (INC) today announced a sem